Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127957 | 1.00 | HSD17B10 (0.39) | HSD17B10KDM1AGRIN2BGRIN2CEPHX2 | |
| SCHEMBL10215476 | 0.87 | HSD17B10 (0.45) | HSD17B10KDM1AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL10215488 | 0.87 | HSD17B10 (0.39) | HSD17B10KDM1AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL2126924 | 0.87 | HSD17B10 (0.45) | HSD17B10KDM1AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL31148270 | 0.87 | HSD17B10 (0.45) | HSD17B10KDM1AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL6468015 | 0.85 | CNR2 (0.39) | HSD17B10GRIN2BGRIN2C | |
| SCHEMBL1347670 | 0.85 | CNR2 (0.39) | HSD17B10GRIN2BGRIN2C | |
| SCHEMBL15130409 | 0.85 | CNR2 (0.39) | HSD17B10GRIN2BGRIN2C | |
| SCHEMBL15113630 | 0.84 | HSD17B10 (0.38) | HSD17B10KDM1AGRIN2BGRIN2CEPHX2 | |
| SCHEMBL2127763 | 0.84 | NR1H2 (0.41) | HSD17B10EPHX2SMN1; SMN2NPC1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | HSD17B10 1274/4885KDM1A 4182/4885GRIN2B 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.